飞翰伦敦办公室起草并向欧洲专利局(EPO)和英国知识产权局(UKIPO)提交和申办专利申请,同时也可按照专利合作条约(PCT)的规定办理专利申请。我们的欧洲专利律师与我们的美国律师合作,共同为客户的专利组合提供战略和成本效益协调服务。我们的专利申办团队能够与客户一道制定和实施各项全球专利组合战略。我们在各技术领域均积累了渊博的知识和丰富的专利申办经验,我们的专业团队与客户紧密合作,共同创建定制化战略,将客户的业务目标、内部程序、产品开发和技术融为一体。同时我们的欧洲专利律师也积累了大量的专利异议和上诉经验,这样他们在办理专利申请时既着眼于专利的执行,同时还防范各种挑战。
我们的伦敦团队汇聚了众多知名专家和经验丰富的专业人士,同时还聘请了经验丰富的青年团队成员,他们每个人都拥有丰富的技术和/或专利申办经验,他们都拥有科学和/或工程技术背景,许多成员都持有其所在技术领域的高级学位或拥有相关行业的从业经历,可以办理几乎涵盖各个行业领域的技术业务,比如石油、天然气和能源勘探、医疗器械、化学、冶金、生物技术、制药、生物制剂和生物仿制药、工业制造、机器人、消费电子产品、计算机软件和商业方法等。
我们的理念是,在起草和办理专利申请时,既要着眼于专利的执行和战略,同时还要将客户的利益和指示牢记于心。我们与客户的科学家密切合作,划定发明的界限并确定发明的范围,努力在发明挖掘/发明披露阶段为客户创造附加值。同时我们也力求有效地沟通客户的发明所取得的成就,并在专利申办过程中展现出发明的界限和优势。对于我们来说,非常重要的是聘请那些能够以高效、低成本方式让我们在高价值全球专利组合的开发中发挥主要作用的团队。
在满足PCT申请要求方面,我们的欧洲专利律师也具有详细的专业知识,包括如何起草并有效地办理满足欧洲、美国以及世界各地要求的“欧洲专利局(EPO)友好型”PCT申请等。我们的专业人士精通世界各地专利局的可专利性和专利程序标准,可以提供协调一致、始终如一且范围广泛的全球性申办战略,实现专利保护的最大化,同时最大程度地降低当地以及外国提交和申请费用。这样就可以建立更为强大的专利组合,并降低纠纷风险,例如涉及到美国同族专利的美国诉讼。而这种协调一致的方法也有助于提高专利申办的质量和效率,进而降低成本。
Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer. Those patents cover a small molecule, fruquintinib, which received approval in China.
Finnegan successfully generated patents to cover protease inhibitor Viracept®, for then startup company Agouron Pharmaceuticals, Inc. Agouron was ultimately acquired by Warner-Lambert (now part of Pfizer) based on the strength of the Viracept® patents, for $2.1 billion.
Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million. Sanofi agreed to pay $3.7 billion to acquire Principia.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Award/Ranking
Asian Legal Business Names Finnegan “International IP Law Firm of the Year”
November 10, 2023
Press Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.